Explore the Clinical Trial Awareness Area

The Clinical Trials Awareness area is your on-site resource for finding a clinical connection. If you are looking for opportunities to be an investigator for clinical trials or ongoing trials for your patients, visit with these companies, located in Lobby E outside the Exhibit Hall.

Bellerophon Therapeutics

Bellerophon Therapeutics is a clinical-stage biotherapeutics company that develops innovative therapies to address significant unmet medical need in the treatment of cardiopulmonary diseases. Bellerophon’s pipeline programs are researching potential indications with INOpulse, a delivery system for inhaled nitric oxide for pulmonary arterial hypertension, pulmonary hypertension in interstitial lung disease, and pulmonary hypertension associated with chronic obstructive pulmonary disease.

Reata Pharmaceuticals

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops novel therapeutics by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Reata is enrolling patients in the Phase 3 CATALYST trial of bardoxolone methyl in patients with CTD-PAH.

Shionogi Inc.

Shionogi & Co., Ltd., is a research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.” Shionogi’s research and development currently target infectious diseases and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives.


VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs. Qsymia® (phentermine and topiramate extended release) is approved by the FDA for chronic weight management. STENDRA® (avanafil) is approved for erectile dysfunction by the FDA and by the EC under the trade name SPEDRA. Tacrolimus is in clinical development for the treatment of patients with pulmonary arterial hypertension.